Novo Nordisk: From Peak Performance To Needing A Booster Shot
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Zacks.com on MSN21h
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...
Semaglutide can also be beneficial to people with type 1 diabetes, clinical trial finds
Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...
Insulin Prices Dropped. But Some Poor Patients Are Paying More.
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
24/7 Wall St19h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
MarketWatch11h
Crude Oil WTI (NYM $/bbl) Front Month
2-Year U.S. Treasury Note Continuous Contract $102.699-0.055-0.05% 5-Year U.S. Treasury Note Continuous Contract $105.977-0.102-0.10% 10-Year U.S. Treasury Note Continuous Contract $108.219-0.109 ...